Local immunomodulation combined to radiofrequency ablation results in a complete cure of local and distant colorectal carcinoma.

Colorectal carcinoma anti-PD1 blockade distant tumor immune response local immunomodulation radiofrequency ablation tumor infiltrating lymphocytes

Journal

Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
Historique:
received: 20 07 2018
revised: 05 11 2018
accepted: 09 11 2018
entrez: 7 2 2019
pubmed: 7 2 2019
medline: 7 2 2019
Statut: epublish

Résumé

Radiofrequency ablation (RFA) of colorectal liver metastases activates a specific T-cell response that is ineffective in avoiding recurrence. Recently, local immunomodulation garnered interests as a way to improve the immune response. We were interested in improving the RFA immune response priming to propose a curative treatment of colorectal cancer (CRC) based on antitumor immunity. First, we demonstrated that the RFA did not increase the tumor infiltrating lymphocytes in secondary distant tumors of patients and in mice model and could not avoid relapse. Remarkably, RFA and in situ immunomodulation with GM-CSF-BCG hydrogel induced complete cure of microscopic secondary lesions in mice, related to a strong specific immune response. Then, we demonstrated that the immune escape of large secondary lesions was reversed by addition of the systemic PD-1 blockade to the in situ immunomodulation. The lack of an effective distant immune response in patients treated with RFA confirmed the relevance of this new combination strategy. Increasing the in situ priming response of radiofrequency ablation provides effective adjuvants to induce an abscopal effect. In the case of large lesions, synergy between PD1 blockade inhibitor, ineffective alone or after single RFA, with in situ immunomodulation, could lead to reconsideration of the use of checkpoint inhibition in metastatic MSS CRC.

Identifiants

pubmed: 30723580
doi: 10.1080/2162402X.2018.1550342
pii: 1550342
pmc: PMC6350685
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

1550342

Références

Lancet. 1999 May 15;353(9165):1689-94
pubmed: 10335805
J Clin Oncol. 2000 Jan;18(1):148-57
pubmed: 10623705
Nature. 2001 Apr 26;410(6832):1107-11
pubmed: 11323675
Ann Oncol. 2001 Jul;12(7):887-94
pubmed: 11521792
Annu Rev Immunol. 2002;20:395-425
pubmed: 11861608
Colorectal Dis. 2003 Sep;5(5):515-7
pubmed: 12925092
J Immunol. 2003 Dec 1;171(11):5727-35
pubmed: 14634080
Ann Surg Oncol. 2004 Feb;11(2):147-56
pubmed: 14761917
Hum Cell. 2003 Dec;16(4):175-82
pubmed: 15147037
Cancer Res. 2004 Jun 1;64(11):4024-9
pubmed: 15173017
Cancer Res. 2004 Sep 1;64(17):6337-43
pubmed: 15342423
J Clin Oncol. 2005 Mar 1;23(7):1358-64
pubmed: 15684312
Recent Results Cancer Res. 2005;165:260-7
pubmed: 15865042
Cancer Treat Rev. 2005 May;31(3):159-72
pubmed: 15923088
Expert Rev Vaccines. 2005 Jun;4(3):329-50
pubmed: 16026248
Cell Stress Chaperones. 2005 Autumn;10(3):221-9
pubmed: 16184767
Eur J Immunol. 2006 Jul;36(7):1805-14
pubmed: 16761313
World J Gastroenterol. 2006 Jun 21;12(23):3716-21
pubmed: 16773688
Urol Oncol. 2006 Sep-Oct;24(5):419-24
pubmed: 16962494
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Pharm Res. 2006 Dec;23(12):2709-28
pubmed: 17096184
Cancer Res. 2007 Jan 1;67(1):425; author reply 426
pubmed: 17210725
J Thorac Oncol. 2006 Sep;1(7):756-61
pubmed: 17409955
Int J Oncol. 2008 Feb;32(2):481-90
pubmed: 18202772
Cell. 2008 Aug 8;134(3):496-507
pubmed: 18692472
Lancet Oncol. 2009 Sep;10(9):877-84
pubmed: 19656725
Cancer Immunol Immunother. 2011 Feb;60(2):273-81
pubmed: 21076828
Int J Hyperthermia. 2011;27(2):132-9
pubmed: 21117923
Cancer Res. 2011 Feb 15;71(4):1263-71
pubmed: 21303976
J Clin Invest. 2011 Jun;121(6):2350-60
pubmed: 21555851
Arch Surg. 2012 Apr;147(4):366-72
pubmed: 22508783
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Diagn Pathol. 2012 Nov 13;7:156
pubmed: 23148481
Oncoimmunology. 2012 Dec 1;1(9):1623-1625
pubmed: 23264915
Cancer Med. 2013 Apr;2(2):117-29
pubmed: 23634280
Mol Ther. 2014 Jan;22(1):18-27
pubmed: 24048441
World J Gastroenterol. 2014 Apr 14;20(14):3738-50
pubmed: 24833840
Clin Cancer Res. 2014 Dec 1;20(23):5995-6005
pubmed: 25255793
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
Oncology (Williston Park). 2014 Nov;28(11):991-1003
pubmed: 25403632
Br J Surg. 2015 Jan;102(1):92-101
pubmed: 25451181
J Clin Oncol. 2015 Jun 10;33(17):1865-6
pubmed: 25667273
Clin Cancer Res. 2016 Mar 1;22(5):1173-1184
pubmed: 26933175
Rev Recent Clin Trials. 2016;11(2):93-8
pubmed: 27028968
World J Gastroenterol. 2016 May 7;22(17):4275-86
pubmed: 27158196
Front Immunol. 2016 Apr 29;7:171
pubmed: 27199993
Exp Mol Med. 2016 Jul 01;48(7):e242
pubmed: 27364892
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28376151
Cell. 2017 Jun 1;169(6):1130-1141.e11
pubmed: 28552348
Eur J Cancer. 2017 Sep;82:16-24
pubmed: 28651158
Int J Cancer. 2017 Oct 15;141(8):1654-1666
pubmed: 28677162
HPB (Oxford). 2018 Jan;20(1):76-82
pubmed: 29029986
Oncotarget. 2017 Jul 21;8(42):72108-72126
pubmed: 29069772
Oncoimmunology. 2017 Sep 21;7(1):e1373231
pubmed: 29296526
J Immunol. 1987 Jun 15;138(12):4185-91
pubmed: 3108384
Cancer. 1987 Aug 1;60(3):326-33
pubmed: 3594369
J Exp Med. 1993 Aug 1;178(2):479-88
pubmed: 7688024
Ann Oncol. 1994;5 Suppl 3:97-104
pubmed: 8204538

Auteurs

Katia Lemdani (K)

EA4340 BCOH, Versailles University, Paris-Saclay University, Boulogne, France.
Department of Surgery and Oncology, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne, France.
CNRS, UTCBS UMR 8258, Paris, France.
Paris Descartes University, Sorbonne-Paris-Cité, Paris, France.
INSERM, UTCBS U1022, Paris, France.
Chimie ParisTech, PSL Research University, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), Paris, France.

Nathalie Mignet (N)

CNRS, UTCBS UMR 8258, Paris, France.
Paris Descartes University, Sorbonne-Paris-Cité, Paris, France.
INSERM, UTCBS U1022, Paris, France.
Chimie ParisTech, PSL Research University, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), Paris, France.

Vincent Boudy (V)

CNRS, UTCBS UMR 8258, Paris, France.
Paris Descartes University, Sorbonne-Paris-Cité, Paris, France.
INSERM, UTCBS U1022, Paris, France.
Chimie ParisTech, PSL Research University, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), Paris, France.
Innovation in Pharmaceutical Formulation Department, Agence Générale des Equipements et des Produits de Santé (AGEPS), AP-HP, Paris, France.

Johanne Seguin (J)

CNRS, UTCBS UMR 8258, Paris, France.
Paris Descartes University, Sorbonne-Paris-Cité, Paris, France.
INSERM, UTCBS U1022, Paris, France.
Chimie ParisTech, PSL Research University, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), Paris, France.
Optical imaging platform LIOPA, Life imaging, PIV, Faculty of Pharmacy, Paris Descartes University, Paris, France.

Edward Oujagir (E)

CNRS, UTCBS UMR 8258, Paris, France.

Olivia Bawa (O)

Institut Gustave Roussy, Unité de pathologie expérimentale de l'IRCIV, Villejuif, France.

Frédérique Peschaud (F)

EA4340 BCOH, Versailles University, Paris-Saclay University, Boulogne, France.
Department of Surgery and Oncology, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne, France.

Jean-François Emile (JF)

EA4340 BCOH, Versailles University, Paris-Saclay University, Boulogne, France.
Pathology Department, Ambroise Paré Hospital, AP-HP, Boulogne, France.

Claude Capron (C)

EA4340 BCOH, Versailles University, Paris-Saclay University, Boulogne, France.
Immunology and hematology Department, Ambroise Paré Hospital, Boulogne, France.

Robert Malafosse (R)

EA4340 BCOH, Versailles University, Paris-Saclay University, Boulogne, France.
Department of Surgery and Oncology, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne, France.

Classifications MeSH